Fulfilling the Promise of Personalized Medicine in gMG: We Are Getting There!
The treatment paradigm for generalized myasthenia gravis (gMG) is changing rapidly with the availability of new antibody tests and targeted treatment options. The treatment landscape for gMG is shifting from reliance on nonspecific immunosuppressants to personalized targeted approaches that address the underlying pathophysiology and achieve disease remission. More than ever, clinicians must engage their patients with gMG in shared decision-making to ensure treatment selection aligns with patient characteristics, preferences, and goals.
Join experts as they describe the burden of gMG, discuss how accounting for patient characteristics can impact treatment selection, review the burden of disease and unmet needs faced by patients with gMG, and enhance clinicians’ ability to identify patient preferences and goals and encourage shared decision-making.
This series is jointly provided by the following partners: